Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03830905
Recruitment Status : Completed
First Posted : February 5, 2019
Last Update Posted : November 16, 2020
Sponsor:
Collaborator:
RSV Therapeutics LLC
Information provided by (Responsible Party):
PHARMENTERPRISES LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.

Condition or disease Intervention/treatment Phase
Influenza Acute Respiratory Viral Infections Drug: XC221 Drug: Placebo Phase 2

Detailed Description:
A double-blind, randomized, placebo-controlled, comparative multicenter study in two groups. A total of 120 patients with uncomplicated influenza or other acute respiratory viral infections are planned to be randomized. Patients will be randomized into 2 groups: 60 patients in the treatment group 200 mg XC221 and 60 patients in the placebo group. The purpose of the clinical trial is to assess the safety, tolerability and efficacy of the drug XC21 in treatment of influenza or other acute respiratory viral infections. The primary objective is to demonstrate the difference between the groups in the time of the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale. The study will consist of the following periods: screening (duration not more than 36 hours from the moment of the first symptoms of the disease), treatment period (3 days), follow-up period (11 ± 1 days after completion of treatment with the study drug/placebo). The duration of participation in the study for each patient is no more than 16 days and 12 hours.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind Randomized Placebo-controlled Comparative Multicenter Study to Assess the Safety, Tolerability and Efficacy of XC221 in a Dose of 200mg Per Day in Patients With Uncomplicated Influenza or Other ARVI
Actual Study Start Date : January 31, 2019
Actual Primary Completion Date : July 3, 2019
Actual Study Completion Date : July 3, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: XC221
XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
 Drug: XC221
Participants will receive 200 mg XC221 once a day during 3 days
Placebo Comparator: Placebo
Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
 Drug: Placebo
Participants will receive Placebo once a day during 3 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to sustained improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. [ Time Frame: From the moment of the first dose up to Day 14 ]

    The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug.

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.



Secondary Outcome Measures :
  1. The time before the onset of persistent improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms (0 points). [ Time Frame: From the moment of the first dose up to Day 14 ]

    The time of the first assessment of 3 consecutive ratings on the Modified Jackson Scale, in which all the clinical symptoms were 0 points.

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.


  2. The time before the onset of persistent improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. [ Time Frame: From the moment of the first dose up to Day 14 ]

    Total score of no more than 3 points, when there is no more than 1 point for each symptom, measured in hours from the moment of taking the first dose of the drug.

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.


  3. Time to normalization of body temperature. [ Time Frame: From the moment of the first dose up to Day 14 ]
    Measured in hours. Normalization means the establishment of body temperature below 37° C without a rise above these values in the subsequent observation period.

  4. The average score according to the Modified Jackson Scale for measuring respiratory symptoms at the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th days. [ Time Frame: From the moment of the first dose up to Day 14 ]

    The average score according to the Modified Jackson Scale on the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th days.

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.


  5. The proportion of patients with a sum of not more than 3 points according to the Modified Jackson Scale for measuring respiratory symptoms at the 1st, 2nd, 3rd, 4th, 5th, 6th , The 7th, 8th days [ Time Frame: From the moment of the first dose up to Day 14 ]

    Score for each symptom should be no higher than 1 point at the 1st, 2nd, 3rd, 4th, 5th, 6th , The 7th, 8th days from the moment of the start of treatment.

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.


  6. The proportion of patients with the normalization of body temperature on the first - the 14th days from the start of treatment; [ Time Frame: From the moment of the first dose up to Day 14 ]
  7. Time to disappearance (0 points) of each of the symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. [ Time Frame: From the moment of the first dose up to Day 14 ]

    Symptom (sneezing, rhinorrhea, nasal congestion, cough, fever, malaise, chills, headache, myalgia, sore throat, tickling, hoarseness) manifested at the level of 2 or 3 points at the first assessment at Visit 0 (Day 0).

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.


  8. The proportion of patients with 0 points score for each of the symptoms according to the Modified Jackson Scale for measuring respiratory symptoms. [ Time Frame: From the moment of the first dose up to Day 14 ]

    Modified Jackson Scale (sneezing, rhinorrhea, nasal congestion, cough, fever, malaise, chills, headache, myalgia, sore throat, tickling, hoarseness) at the 2nd, 3rd 2nd, 4th, 5th, 6th, 7th and 8th days from the moment of the start of treatment in a population of patients with the corresponding symptom shown at the level of 2 or 3 points at Visit 0 (Day 0).

    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.


  9. The proportion of patients with a detected viral pathogen [ Time Frame: From the moment of the first dose up to Day 14 ]
    The proportion of patients with a detected viral pathogen at Visit 0, Visit 4 and Visit 6.

  10. The proportion of patients with a detected viral pathogen at Visit 4 and Visit 6 compared with the initial proportion of such patients in the XC221. [ Time Frame: From the moment of the first dose up to Day 14 ]
  11. The frequency of adverse events (AEs) and serious adverse events (SAEs) in the XC221 treatment group and in the placebo group. [ Time Frame: From the moment of the first dose up to Day 14 ]

Other Outcome Measures:
  1. The average concentration of MxA protein in the blood at Visit 1, Visit 4 and at Visit 6. [ Time Frame: From Day 1 up to Day 6 ]
  2. Changes in the concentration of MxA protein in the blood at Visit 4 and at Visit 6 compared to Visit 1. [ Time Frame: From Day 1 up to Day 6 ]
  3. The average concentration of C-reactive protein in the blood at Visit 1, Visit 4 and Visit 6. [ Time Frame: From Day 1 up to Day 6 ]
  4. Changes in the concentration of C-reactive protein in the blood at Visit 4 and Visit 6 compared to Visit 1. [ Time Frame: From Day 1 up to Day 6 ]
  5. The average concentration of cytokines at Visit 1, Visit 4 and at Visit 6. [ Time Frame: From Day 1 up to Day 6 ]
    The average concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN- γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in blood at Visit 1, Visit 4 and at Visit 6.

  6. The percentage change in the concentration of cytokines at Visit 4 and at Visit 6 compared with Visit 1. [ Time Frame: From Day 1 up to Day 6 ]
    The percentage change in the concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN -γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3 , MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in blood at Visit 4 and Visit 6 compared with Visit 1.

  7. Correlation between the concentration of cytokines/chemokines and the assessment of the Modified Jackson scale for measuring respiratory symptoms (in dynamics). [ Time Frame: From the moment of the first dose up to Day 14 ]
    Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.

  8. The average concentration of cytokines in a smear from the mucosa of the nasopharynx and oropharyngeal at Visit 1, Visit 4 and Visit 6 [ Time Frame: From Day 1 up to Day 6 ]
    The average concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN- γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in a smear from the mucosa of the nasopharynx and oropharyngeal at Visit 1, Visit 4 and Visit 6.

  9. The percentage change in the concentration of cytokines in a smear from the mucous membrane of the nasopharynx and oropharynx of patients on Visit 4 and on Visit 6 compared to Visit 1. [ Time Frame: From Day 1 up to Day 6 ]
    The percentage change in the concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-α, Gro-β, I-309, IFN- γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1α, MIP-1δ, MIP-3α, MIP-3β, MPIF-1, SCYB16, SDF-1α + β, TARC, TECK, TNF-α in a smear from the mucous membrane of the nasopharynx and oropharynx of patients on Visit 4 and on Visit 6 compared to Visit 1.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Both sexes aged 18 years and older.
  2. Clinically diagnosed influenza or ARVI mild or moderate severity.
  3. Patient's body temperature ≥37.5ºС and at least 1 symptom from Modified Jackson Scale estimated more than 2 points.
  4. Uncomplicated course of influenza or ARVI based on clinical estimations.
  5. The first 36 hours from the beginning of symptoms of influenza or ARVI.
  6. Women of reproductive age (who are not in menopause and who have not undergone surgical sterilization) and men who have sexual activity should use a reliable method of contraception (acceptable methods of contraception in this study are: intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, a double barrier method (condom and diaphragm with spermicide) throughout the study period.
  7. Compliance with the treatment regimen, visits and laboratory examinations provided by the protocol.
  8. Signed Informed Consent Form.

Exclusion Criteria:

  1. Complications of influenza or ARVI (including the presence / development of bacterial infection).
  2. The need for inpatient treatment of influenza and ARVI.
  3. Hypersensitivity to excipients of the drug XC221 or placebo.
  4. Antiviral medications 7 days prior to screening (antiviral agents, interferons and interferon inducers, drugs that have immunomodulating action) or anti-infective agents of systemic or local action.
  5. Severe infection with signs of cardiovascular insufficiency development and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions, polyradiculoneuritis, neuritis).
  6. Signs of of viral pneumonia symptoms (the presence of two or more of the following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of percussion sound with a symmetrical evaluation of the upper and lower sections of the lungs).
  7. Infectious diseases during the last week before including into the study.
  8. Bronchial asthma, COPD, pulmonary emphysema in history.
  9. History of increased convulsive activity.
  10. Severe, decompensated or unstable somatic diseases (any diseases or conditions that are life-threatening or may worsen the patient's prognosis, and make him/her ineligible for the clinical study).
  11. History of oncological diseases, HIV, tuberculosis.
  12. Drug or alcohol abuse.
  13. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
  14. Participation in any other clinical trial in the last 90 days.
  15. Pregnancy or lactation.
  16. Military or prison populations.
  17. Impossibility or inability to comply with the study procedures.
  18. A member of the investigator's family or other person interested in the results of the study.
  19. Deviations from laboratory standards, which prevent the inclusion of the patient in the study according to the Investigator.
  20. A history of kidney failure.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03830905


Locations
Layout table for location information
Russian Federation
Federal State Budgetary Institution of Health "Northern Medical Clinical Center named after NA Semashko of the Federal Medical and Biological Agency"
Arkhangelsk, Russian Federation, 163000
Regional State Budgetary Institution of Health "Belgorod Regional Clinical Hospital of St. Joasaph"
Belgorod, Russian Federation, 308007
City Clinical Hospital №9
Izhevsk, Russian Federation, 426063
Kuban State Medical University
Krasnodar, Russian Federation, 350063
State budget institution of health care of the Moscow region "Krasnogorsk city hospital number 1"
Krasnogorsk, Russian Federation, 143408
Non-governmental Healthcare Institution "N.A.Semashko Road Clinical Hospital at the Lyublino station of the open joint-stock company "Russian Railways"
Moscow, Russian Federation, 109386
Ryazan State Medical University n.a. Pavlov
Ryazan', Russian Federation, 390026
Federal State Budgetary Educational Institution of Higher Education "Ryazan State Medical University named after Academician I.P. Pavlova" of the Ministry of Health of the Russian Federation
Ryazan, Russian Federation, 390026
The Center for Prevention and Fight about AIDS and Infectious Diseases
Saint Petersburg, Russian Federation, 190103
The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation
Saint Petersburg, Russian Federation, 197110
Research Institute of Influenza
Saint Petersburg, Russian Federation, 197376
City Clinical Hospital №40 of Kurortny District
Saint Petersburg, Russian Federation, 197706
LLC "Aurora Medi"
St. Petersburg, Russian Federation, 193232
LLC "Astarta"
St. Petersburg, Russian Federation, 199226
Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Health of the Russian Federation
Yaroslavl, Russian Federation, 150000
State Budgetary Healthcare Institution (SBHI) of Yaroslavl region
Yaroslavl, Russian Federation, 150007
Sponsors and Collaborators
PHARMENTERPRISES LLC
RSV Therapeutics LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: PHARMENTERPRISES LLC
ClinicalTrials.gov Identifier: NCT03830905    
Other Study ID Numbers: ARI-XC221-03
First Posted: February 5, 2019    Key Record Dates
Last Update Posted: November 16, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Virus Diseases
Respiratory Tract Infections
Infections
 Orthomyxoviridae Infections
RNA Virus Infections
Respiratory Tract Diseases